SECsense Logo

Intra-Cellular Therapies, Inc. 8-K Report: Key Developments Unveiled

$ITCI
Form 8-K
Filed on: 2025-02-21
Source
Intra-Cellular Therapies, Inc. 8-K Report: Key Developments Unveiled

Based on the provided section of the financial report, here are the key points extracted:

  1. Entity Information:
  • Company Name: Intra-Cellular Therapies, Inc.
  • CIK Number: 0001567514
  • SEC File Number: 001-36274
  • State of Incorporation: Delaware (DE)
  • EIN: 36-4742850
  • Address: 135 Route 202/206 Suite 6, Bedminster, NJ 07921
  • Contact Number: (646) 440-9333
  1. Filing Details:
  • Filing Type: 8-K
  • Filing Date: February 21, 2025
  1. Stock Information:
  • Common Stock Symbol: ITCI
  • Exchange: NASDAQ
  1. Period of Report:
  • Start Date: February 21, 2025
  • End Date: February 21, 2025

Insights:

  • The report is a Form 8-K, which is typically used to report major events that shareholders should know about, indicating that there may be significant news or developments for Intra-Cellular Therapies, Inc.
  • The filing date and the reporting period are the same, suggesting that the report may contain immediate or timely information relevant to the company’s operations or financial condition as of that date.
  • The company operates in the healthcare sector, likely focusing on therapies, as suggested by its name, which may be relevant for investors looking at pharmaceutical or biotech investments.

Overall, further details would be necessary to understand the specific content of the 8-K filing, as it could include various material events, financial results, or corporate governance updates.